Currently out of the existing stock ratings of Marc Frahm, 15 are a BUY (62.5%), 9 are a HOLD (37.5%).

Marc Frahm

Work Performance Price Targets & Ratings Chart

Analyst Marc Frahm, currently employed at TD COWEN, carries an average stock price target met ratio of 70.58% that have a potential upside of 13.29% achieved within 161 days.

Marc Frahm’s has documented 49 price targets and ratings displayed on 14 stocks. The coverage is on Healthcare, Pharmaceuticals sectors.

Most recent stock forecast was given on TBPH, Theravance Biopharma at 23-Mar-2026.

Wall Street Analyst Marc Frahm

Analyst best performing recommendations are on TBPH (THERAVANCE BIOPHARMA).
The best stock recommendation documented was for INCY (YTE) at 10/29/2025. The price target of $101 was fulfilled within 5 days with a profit of $10.82 (12%) receiving and performance score of 24.

Average potential price target upside

of $20.37 (32%) on INCY (YTE).
of $1.77 (20.05%) on TBPH (THERAVANCE BIOPHARMA).
of $0.4 (1.12%) on IMGO (IMAGO BIOSCIENCES).

TBPH Theravance Biopharma IMGO Imago Biosciences DAWN Day One Biopharmaceuticals INCY yte XLO Xilio Development SANA Sana Biotechnology BPMC Blueprint Medicines Corp CNST Constellation Pharmaceuticals AGIO Agios Pharm GLUE Monte Rosa Therapeutics NUVL Nuvalent RVMD Revolution Medicines STTK Shattuck Labs ODT Odonate Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Debanjana Chatterjee (JONESTRADING)